Tag:
Takeda
Latest Headlines
Latest Headlines
Amag pulls anemia drug batch after Swiss patient dies
Amag Pharmaceuticals and partner Takeda have run into a snag in Switzerland. Japan-based Takeda is recalling a batch of Amag's anemia drug Feraheme, sold as Rienso in the Swiss market, after several reports of hypersensitivity reactions, one of them fatal.
UPDATED: Deborah Dunsire exits as Takeda cuts CEO role in Millennium shakeup
Millennium CEO Deborah Dunsire is retiring and her business development chief Anna Protopapas will step in to head the oncology business of Takeda Pharmaceutical. The Japanese drugmaker revealed the management shakeup in a terse announcement today.
Takeda takes on Sanofi with $250M dengue buyout
In 1977, dengue fever experts predicted a vaccine could be ready in 10 years. That prediction proved wildly optimistic, leaving the 2.5 billion people at risk from dengue fever without protection. Sanofi is at the forefront of dengue vaccine research but now faces a challenger from Japan.
UPDATED: Takeda beefs up new vaccines arm with $250M bolt-on buyout of Inviragen
A couple of months after moving its experimental dengue vaccine into the second phase of a mid-stage study, Fort Collins, CO-based Inviragen has been snapped up by Takeda in a $250 million deal.
Takeda persuades Actos judge to toss $6.5M jury verdict
The $6.5 million jury verdict in Takeda Pharmaceuticals' first Actos trial didn't last long. Judge Kenneth Freeman tossed out the jury's judgment, saying that plaintiffs' lawyers didn't prove that Jack Cooper's bladder cancer was linked to his use of Actos.
Jury hits Takeda with $6.5M judgment in first Actos liability case
Score one for the plaintiffs in Takeda Pharmaceuticals' Actos litigation. A California jury weighed in against the drugmaker, deciding that Takeda didn't do enough to warn patient Jack Cooper about a heightened risk of bladder cancer.
Takeda in more trouble at home over recall of mislabeled vials
Japan's Takeda has gotten into more local hot water over the recall earlier this year of a lot of its Alinamin-F5 dietary supplement sold in Japan for vitamin B1 deficiency.
Takeda taps Scripps as the pharma extends early-stage pipeline
Takeda Pharmaceutical is leaning on academics to support its efforts to discover new drugs. The Japanese drug giant has expanded an alliance with the Scripps Research Institute outpost in Jupiter, FL, hunting for new drugs to combat multiple diseases.
Takeda snags rights to lupus drugs from Seattle upstart in $255M deal
Takeda Pharmaceutical has struck a deal which fuels its ambitions for growth in immunology. The Japanese drugmaker and Seattle-based startup Resolve Therapeutics have agreed to terms for a partnership for Resolve's pre-clinical program targeting lupus.
Affymax explores manufacturing for ties to fatal drug reactions
Drugmakers Affymax and Takeda are investigating whether manufacturing is playing a role in the allergic reactions that have resulted in three deaths and led it to recall all of its anemia drug Omontys from the market.
